| 头孢丙烯在下呼吸道细菌感染患者的药代动力学研究 |
| 投稿时间：2006-04-15 点此下载全文 |
| 引用本文：刘新宇,吴芳.头孢丙烯在下呼吸道细菌感染患者的药代动力学研究[J].药学实践杂志,2006,(3):144~146 |
| 摘要点击次数: 716 |
| 全文下载次数: 222 |
|
|
| 中文摘要:目的:通过研究下呼吸道细菌感染患者的头孢丙烯临床药代动力学参数,为临床选择合理给药方案提供依据。方法:用HPLC法测定10例下呼吸道细菌感染患者连续给药5d后的稳态血药浓度,数据用3P97 药物动力学模拟系统处理。结果:头孢丙烯的药时曲线符合二室开放模型,主要药代动力学参数:t1/2为 (1.55±0.17)h,MRT为(2.52±0.15)h,Cmax为(13.32±1.28)μg／mL,tmax为(1.41±0.31)h,AUC0-10为 (31.68±7.68)μg h／mL。结论:口服头孢丙烯片500mg,每天2次,能获得控制下呼吸道细菌感染的有效治疗浓度。 |
| 中文关键词:头孢丙烯 药代动力学 高效液相色谱法 下呼吸道细菌感染 |
| |
| The pharmacokinetics study of cefprozil in patients with low respiratory tract bacterial infections |
|
|
| Abstract:Objective:To offer the evidence for reasonable dosage regimen by the pharmacokinetics study of cefprozil in patients with low respiratory tract bacterial infections. Methods:The cefprozil concentration in plasma was determined by the high performance liquid chromatography method. The pharmacokinetic parameters were obtained by using 3P97 imitate program. Results:With oral multiple - dose of 500mg of cefprozil twice over 5 consecutive days, the main pharmacokinetic parameters obtained from the patients were as follows :t1/2 was (1.55±0.17)h,MRT was (2.52 ±0. 15)h.Cmax was ( 13.32 ± 1. 28)μg/mL,tmax was (1.41±0.31)h,AUC0-10 was (31.68 ±7.68)μg·h/mL. Conclusions:Cefprozil 500mg, bid orally may be effective against low respiratory tract bacterial infections. |
| keywords:cefprozil pharmacokinetics HPLC low respiratory tract bacterial infections |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
